Figure 1
Figure 1. The role of Gα12 and Gαq in vWF secretion and primary hemostasis. (A) vWF levels in plasma from WT vs Gα12−/−, Gα11−/−, EC-Gαq−/−;Gα11−/−, and EC-Gα13−/−;Gα12−/− mice. *P < .05 vs WT; n = 6/group. (B) Representative vWF multimer gel from WT, Gα12−/−, and Gα11−/− mouse plasma. Quantitative multimer analysis shows no difference between Gα12−/− (n = 3) and WT or Gα11−/− mouse vWF. (C) Constitutive and PAR-1 agonist peptide-induced vWF release from WT, Gα12−/−, and EC-Gαq/;Gα11−/− isolated perfused mouse lungs. Time-course of basal and PAR-1-specific peptide TFLLR-evoked vWF release into mouse lung perfusate. (D) vWF in WT, Gα12−/− and EC-Gαq−/−;Gα11−/− mouse lung extracts from untreated lungs or after PAR-1 peptide stimulation. *P < .05 vs WT + TFLLR; n = 6/group. See also supplemental Figure 1B.

The role of Gα12 and Gαq in vWF secretion and primary hemostasis. (A) vWF levels in plasma from WT vs Gα12−/−, Gα11−/−, EC-Gαq−/−;Gα11−/−, and EC-Gα13−/−;Gα12−/− mice. *P < .05 vs WT; n = 6/group. (B) Representative vWF multimer gel from WT, Gα12−/−, and Gα11−/− mouse plasma. Quantitative multimer analysis shows no difference between Gα12−/− (n = 3) and WT or Gα11−/− mouse vWF. (C) Constitutive and PAR-1 agonist peptide-induced vWF release from WT, Gα12−/−, and EC-Gαq/;Gα11−/− isolated perfused mouse lungs. Time-course of basal and PAR-1-specific peptide TFLLR-evoked vWF release into mouse lung perfusate. (D) vWF in WT, Gα12−/− and EC-Gαq−/−;Gα11−/− mouse lung extracts from untreated lungs or after PAR-1 peptide stimulation. *P < .05 vs WT + TFLLR; n = 6/group. See also supplemental Figure 1B.

Close Modal

or Create an Account

Close Modal
Close Modal